Abstract
To improve the timeliness of health care delivery to patients with meningococcal disease, the early disease evolution and clinical manifestation at admission were studied in all 752 patients with invasive meningococcal disease in the Netherlands in 2003–2005. Eighty-eight percent (88%) had serogroup B disease. The case fatality rate (CFR) was 6.7% overall, but reached 16% among adults over 50 years of age. The CFR was similar for serogroups B (6.3%) and C (5.2%). Admission followed 17 h (median) after the onset of symptoms. The CFR in patients admitted within 12 h, 12–18 h, 18–36 h or >36 h after the first symptoms was 10.2, 7.8, 3.5 and 2.2%, respectively. Only 60% of patients had skin lesions, and admission followed 2 h (median) later. Earlier recognition can be achieved when non-petechial clues are included in the diagnosis. A short duration of disease before admission is a simple tool in the recognition of patients with severe disease.
Similar content being viewed by others
Reference
van Deuren M, Brandtzaeg P, van der Meer JW (2000) Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbial Rev 13:144–166
Brandtzaeg P, van Deuren M (2005) Meningococcal infections at the start of the 21st century. Adv Pediatr 52:129–162
Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME (2004) Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364:365–367
de Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van Derende A (2006) Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 25:79–80
Larrauri A, Cano R, García M, Mateo S (2005) Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 23:4097–4100
Mooney JD, Christie P, Robertson C, Clarke SC (2004) The impact of meningococcal serogroup C conjugate vaccine in Scotland. Clin Infect Dis 39:349–356
Halstensen A, Pedersen SH, Haneberg B, Bjorvatn B, Solberg CO (1987) Case fatality of meningococcal disease in western Norway. Scand J Infect Dis 19:35–42
Smith I, Caugant DA, Høiby EA, Wentzel-Larsen T, Halstensen A (2006) High case-fatality rates of meningococcal disease in Western Norway caused by serogroup C strains belonging to both sequence type (ST)-32 and ST-11 complexes, 1985–2002. Epidemiol Infect 134:1195–1202
Wood AL, O’Brien SJ (1996) How long is too long? Determining the early management of meningococcal disease in Birmingham. Public Health 110:237–239
Trotter C, Samuelsson S, Perrocheau A, de Greeff S, de Melker H, Heuberger S, Ramsay M (2005) Ascertainment of meningococcal disease in Europe. Euro Surveill 10:247–250
de Greeff SC, Spanjaard L, Dankert J, Hoebe CJ, Nagelkerke N, de Melker HE (2006) Underreporting of meningococcal disease incidence in the Netherlands: results from a capture–recapture analysis based on three registration sources with correction for false positive diagnoses. Eur J Epidemiol 21:315–321
Rothman KJ (2002) Epidemiology: an introduction. Oxford University Press, New York
Netherlands Reference Laboratory for Bacterial Meningitis (AMC/RIVM) (2006) Bacterial meningitis in the Netherlands; annual report 2005. University of Amsterdam, Amsterdam
Ramsay M, Kaczmarski E, Rush M, Mallard R, Farrington P, White J (1997) Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales. Commun Dis Rev 7:R49–R54
Paret G, Keller N, Barzilai A, Zemach M, Guttman D, Vardi A, Shatzberg G, Cohen H, Barzilay Z (1999) Invasive meningococcal disease: patient and strain characteristics set new challenge for prevention and control. Infection 27:261–264
Shigematsu M, Davison KL, Charlett A, Crowcroft NS (2002) National enhanced surveillance of meningococcal disease in England, Wales and Northern Ireland, January 1999–June 2001. Epidemiol Infect 129:459–470
Smith I, Bjørnevik AT, Augland IM, Berstad A, Wentzel-Larsen T, Halstensen A (2006) Variations in case fatality and fatality risk factors of meningococcal disease in Western Norway, 1985–2002. Epidemiol Infect 134:103–110
Bøvre K, Frøholm LO, Gaustad P, Holten E, Høiby EA (1983) Some agent characteristics and their coexistence related to occurrence and severity of systemic meningococcal disease in Norway, Winter 1981–1982. NIPH Ann 6:75–84
Waage A, Halstensen A, Espevik T (1987) Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1:355–357
Brandtzaeg P, Kierulf P, Gaustad P, Skulberg A, Bruun JN, Halvorsen S, Sørensen E (1989) Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 159:195–204
van Deuren M, Neeleman C, Van’t Hek LG, van der Meer JW (1998) A normal platelet count at admission in acute meningococcal disease does not exclude a fulminant course. Intensive Care Med 24:157–161
Stiehm ER, Damrosch DS (1966) Factors in the prognosis of meningococcal infection. Review of 63 cases with emphasis on recognition and management of the severely ill patient. J Pediatr 68:457–467
Sinclair JF, Skeoch CH, Hallworth D (1987) Prognosis of meningococcal septicaemia. Lancet 2:38
Riordan FA, Marzouk O, Thomson AP, Sills JA, Hart CA (2002) Prospective validation of the Glasgow Meningococcal Septicaemia Prognostic Score. Comparison with other scoring methods. Eur J Pediatr 161:531–537
Thompson MJ, Ninis N, Perera R, Mayon-White R, Phillips C, Bailey L, Harnden A, Mant D, Levin M (2006) Clinical recognition of meningococcal disease in children and adolescents. Lancet 367:397–403
Tønjum T, Nilsson F, Bruun JN, Haneberg B (1983) The early phase of meningococcal disease. NIPH Ann 6:175–181
Louria DB, Sen P, Kapila R, Johnson E, Smith L, Roberts R (1985) Anterior thigh pain or tenderness. A diagnostically useful manifestation of bacteremia. Arch Intern Med 145:657–658
Inkelis SH, O’Leary D, Wang VJ, Malley R, Nicholson MK, Kuppermann N (2002) Extremity pain and refusal to walk in children with invasive meningococcal disease. Pediatrics 110:e3
Granier S, Owen P, Pill R, Jacobson L (1998) Recognising meningococcal disease in primary care: qualitative study of how general practitioners process clinical and contextual information. BMJ 316:276–279
Health Protection Agency (2008) Meningococcal disease. Available online at: http://www.hpa.org.uk/infections/topics_az/meningo/guidelines.htm
Hackett SJ, Guiver M, Marsh J, Sills JA, Thomson AP, Kaczmarski EB, Hart CA (2002) Meningococcal bacterial DNA load at presentation correlates with disease severity. Arch Dis Child 86:44–46
Øvstebø R, Brandtzaeg P, Brusletto B, Haug KB, Lande K, Høiby EA, Kierulf P (2004) Use of robotized DNA isolation and real-time PCR to quantify and identify close correlation between levels of Neisseria meningitidis DNA and lipopolysaccharides in plasma and cerebrospinal fluid from patients with systemic meningococcal disease. J Clin Microbiol 42:2980–2987
Acknowledgements
We thank all of the involved physicians and Public Health Services staff concerned with infectious diseases in the Netherlands for collecting and documenting the data requested in the enhanced surveillance questionnaire.
Author information
Authors and Affiliations
Corresponding author
Additional information
Declaration of interest: none.
Rights and permissions
About this article
Cite this article
de Greeff, S.C., de Melker, H.E., Schouls, L.M. et al. Pre-admission clinical course of meningococcal disease and opportunities for the earlier start of appropriate intervention: a prospective epidemiological study on 752 patients in the Netherlands, 2003–2005. Eur J Clin Microbiol Infect Dis 27, 985–992 (2008). https://doi.org/10.1007/s10096-008-0535-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-008-0535-1